Duncan Hannant

Duncan Hannant

Auto-generated profile, based on publicly available information

Duncan Hannant

University of Nottingham, Nottingham, United Kingdom

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2014 in Epidemiology and Infection
Verified
Journal Article
Closed access
GHG. Hestvik
G. Hestvik
EWE. Warns-Petit
E. Warns-Petit
LSL. A. Smith
L. A. Smith
NFN. J. Fox
N. J. Fox
HUH. Uhlhorn
H. Uhlhorn
DGD. Gavier-Widen
D. Gavier-Widen
SUMMARY: The bacteriumFrancisella tularensiscauses the vector-borne zoonotic disease tularemia, and may infect a wide range of hosts including invertebrates, mammals and birds. Transmission to humans occurs through contact with infected animals or contaminated environments, or through arthropod vectors. Tularemia has a broad geographical distribution, and there is evidence which suggests local emergence or re-emergence of this disease in Europe. This review was developed to provide an update on the geographical distribution ofF. tularensisin humans, wildlife, domestic animals and vector species, to identify potential public health hazards, and to characterize the epidemiology of tularemia in Europe. Information was collated on cases in humans, domestic animals and wildlife, and on reports of detection of the bacterium in arthropod vectors, from 38 European countries for the period 1992–2012. Multiple international databases on human and animal health were consulted, as well as published reports in the literature. Tularemia is a disease of complex epidemiology that is challenging to understand and therefore to control. Many aspects of this disease remain poorly understood. Better understanding is needed of the epidemiological role of animal hosts, potential vectors, mechanisms of maintenance in the different ecosystems, and routes of transmission of the disease.

1 March 1998 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Open access
DLD.P Lunn
D.P Lunn
MHM.A Holmes
M.A Holmes
DAD.F Antczak
D.F Antczak
NAN Agerwal
N Agerwal
JBJessica Baker
Jessica Baker
KVKaren E Vagnoni
Karen E Vagnoni
The final assignment of antibody clusters for leucocyte antigens and immunoglobulins, as described in detail in Sections 3 and 4, is summarized in Table 4. Together with other mAbs developed outside of ELAW II (Table 9) this pool of reagents represent a powerful array of tools for the study of equine immunity. The Second Equine Leucocyte Antigen Workshop made considerable advances in pursuing the objectives of establishing the specificities of mAbs and achieving consensus on the nomenclature for equine leucocyte and immunoglobulin molecules. Of equal importance, several productive collaborations were fostered among the participating laboratories and observers. Overall, enormous advances have been made in the past decade since mAbs specific for equine leucocyte antigens and immunoglobulins were first reported. There remains enormous scope and need for further studies of equine leucocyte antigens and immunoglobulins, both for the purposes of comparative immunology and for the good of the horse. In the future novel techniques will be required to develop reagents for specific target antigens such as the orthologues of the CD25 or CD45 isoforms. In studies of equine immunoglobulins the functional role of the IgG isotypes must be better established, reagents for IgE must be developed, and cloning of the immunoglobulin heavy chain genes will be essential if the complexities of the IgG sub-isotypes are to be elucidated. The tasks still facing the currently small group of equine immunologists throughout the world remain formidable, and will only be tackled successfully in a spirit of collaboration.

8 May 2006 in Vaccine
Verified
Journal Article
Closed access
Romain PaillotRomain Paillot
Romain Paillot
DHD Hannant
D Hannant
JKJ Kydd
J Kydd
Janet Mary DalyJanet Mary Daly
Janet Mary Daly

1 November 1994 in Equine Veterinary Journal
Verified
Journal Article
Closed access
PDF file
JKJulia H. Kydd
Julia H. Kydd
KSK. C. Smith
K. C. Smith
DHD. Hannant
D. Hannant
GLGeorgia J. Livesay
Georgia J. Livesay
JMJennifer A. Mumford
Jennifer A. Mumford

1 May 2006 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
JKJulia H. Kydd
Julia H. Kydd
HTHugh G.G. Townsend
Hugh G.G. Townsend
DHDuncan Hannant
Duncan Hannant

1 April 1994 in Epidemiology and Infection
Verified
Journal Article
Closed access
PDF file
JMJ. A. Mumford
J. A. Mumford
HWH. Wilson
H. Wilson
DHD. Hannant
D. Hannant
DJD. M. Jessett
D. M. Jessett
SUMMARY: Equine influenza vaccines containing inactivated whole virus and Carbomer adjuvant stimulated higher levels and longer lasting antibody to haemagglutinin in ponies than vaccines of equivalent antigenic content containing aluminium phosphate adjuvants. Five months after the third dose of vaccine containing Carbomer adjuvant, ponies were protected against clinical disease induced by an aerosol of virulent influenza virus (A/equine/Newmarket/79, H3N8). In contrast ponies which received vaccine containing aluminium phosphate adjuvant were susceptible to infection and disease. There was an inverse correlation between prechallenge levels of antibody detected by single radial haemolysis (SRH) and duration of virus excretion, pyrexia and coughing. All ponies with antibody levels equivalent to SRH zones of ≥ 154 mm2were protected against infection and all those with levels ≤ 85 mm2were protected from disease.